# TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 at HIV Glasgow 2026

> TaiMed Biologics will present 24-week Phase 2a data on its TMB-365/TMB-380 antibody regimen at HIV Glasgow 2026, testing viral suppression.

- Published: 2026-11-05T00:39:31+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-05/taimed-biologics-hiv-glasgow-phase-2a-data
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/05/3395971/0/en/taimed-biologics-to-present-24-week-phase-2a-data-on-tmb-365-tmb-380-maintenance-regimen-at-hiv-glasgow-2026.html)

## Key takeaways

- TaiMed Biologics will present 24-week Phase 2a data on TMB-365/TMB-380, given every eight weeks, at HIV Glasgow 2026.
- Martin Markowitz of Columbia University Irving Medical Center is the presenting author for both the oral and poster sessions.
- TaiMed completed enrollment in its Phase 2b study of TMB-365/380 ahead of schedule and expects an interim analysis by year-end 2026.

[TaiMed Biologics](https://akta.pro/company-profiles/0009tie/taimed-biologics) will present 24-week clinical data from its Phase 2a maintenance study of the TMB-365/TMB-380 combination regimen, administered every eight weeks, in an oral presentation at HIV Drug Therapy Glasgow 2026, the company said in a [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/05/3395971/0/en/taimed-biologics-to-present-24-week-phase-2a-data-on-tmb-365-tmb-380-maintenance-regimen-at-hiv-glasgow-2026.html) release. The conference runs November 8–11, 2026, in Glasgow, Scotland.

## TaiMed's Phase 2a Oral Presentation at HIV Glasgow

TaiMed Biologics is a commercial-stage CD4-targeted biologics company developing antibody-based therapies for long-acting HIV treatment. The Phase 2a study evaluated whether TMB-365/TMB-380, given every eight weeks, could maintain viral suppression as a stand-alone regimen in people living with HIV-1 who switched from combination antiretroviral therapy.

"The Phase 2a study evaluated whether TMB-365/TMB-380, given every eight weeks, could maintain viral suppression as a stand-alone regimen in people living with HIV-1 who switched from combination antiretroviral therapy," said Jimmy Chang, PhD, Chief Executive Officer of TaiMed Biologics. "HIV Glasgow brings together clinicians and researchers focused on HIV treatment, and we look forward to sharing these results and discussing the role an antibody-only, long-acting regimen could play in maintenance treatment."

The oral presentation, titled "A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection (O31)," is scheduled for November 10, 2026, from 10:55 AM to 11:07 AM GMT in the Clyde room at the Scottish Event Campus. Martin Markowitz, MD, of Columbia University Irving Medical Center, is the presenting author. The session is titled Novel Strategies and Treatment.

TaiMed will also present an encore poster on its Phase 1 single-dose escalation study of TMB-365, which was presented orally at IDWeek 2026. The poster, titled "Single-dose escalation study of TMB-365 in people living with HIV: safety, pharmacokinetics and antiviral activity (P040)," is scheduled for November 8–11, 2026, in Exhibition Hall 4 at the Scottish Event Campus. Markowitz is also the presenting author for the poster.

## TaiMed's Phase 2b Enrollment and Market Estimates

According to akta.pro [company records](https://akta.pro/company-data), TaiMed completed Phase 2b enrollment for TMB-365/380 long-acting dual antibody HIV maintenance therapy in May 2025, with 75 participants and a 48-week duration. The same records estimate peak annual sales potential for TMB-365/380 at up to $4 billion and the first-line long-acting HIV maintenance therapy market at $10 billion globally.

## Earlier TMB-365 Data and Trogarzo Approval

In October 2026, TaiMed presented Phase 1 data for TMB-365 at IDWeek 2026, showing antiviral activity and tolerability in 25 HIV-positive participants, according to GlobeNewswire. Earlier that month, the company said it would present clinical data on TMB-365 and in vitro susceptibility data for the TMB-365/TMB-380 combination at IDWeek 2026 in Washington, D.C. In July 2026, TaiMed announced it had received the Drug License Collection Notice from Taiwan's Food and Drug Administration for its HIV therapy Trogarzo (ibalizumab), according to GlobeNewswire.

## TaiMed's Phase 2b Interim Analysis Timeline

TaiMed expects an interim analysis from its Phase 2b study of TMB-365/380 by year-end 2026 and plans to submit a Breakthrough Therapy Designation to the FDA if outcomes remain positive, according to BioSpace.

## Companies in this story

- [TaiMed Biologics company profile](https://akta.pro/company-profiles/0009tie/taimed-biologics) · website: http://www.taimedbiologics.com

---
News for Agent · https://newsforagent.com/llms.txt